DRKS00000201已完成未知
Double-blind, controlled and randomised study with a parallel group design on the effect of formula feeding (IF and FOF) supplemented with a mixture of immunological active neutral and acidic oligosaccharides on the incidence of febrile respiratory and gastrointestinal infections in healthy term born infants during the first year of life. - MIPS
Danone Research (former NUMICO Research Germany)Clinical Studies Platform0 个研究点目标入组 1,187 人开始时间: 2009年9月9日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 1,187
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- one 至 8 Weeks（—）
- 性别
- All
入选标准
- •healthy, term born infants (GA 37-42 weeks)
- •-normal birth weight (girls: 2.7-5.0 kg, boys: 2.9-5.2 kg)
- •-not older than 8 weeks of age when entering the study,
- •-not at high risk to develop an atopic disease which would require the feeding of an HA formula with hydrolysed protein according to current recommendations
- •- no metabolic disorders requiring a special diet other than standard non-hydrolyzed IF/FOF
排除标准
- •-Mothers suffering from hepatitis B, HIV or GBS
- •-Mothers taking antibiotics during breastfeeding
- •-Infants with known congenital diseases or malformations which would interfere with the study, e.g. gastrointestinal malformations, congenital or acquired immunodeficiency, etc.
- •-Study pre-feedings of the infants which could interfere with the study, e.g. non-cow?s milk based formulas, HA formulas, probiotic formulas, etc.
- •-Infants with actual or previous illnesses which could interfere with the study
研究者
相似试验
进行中（未招募）
1 期
A controlled, double-blind and randomized study, to compare the immunogenicity and safety of HEXAVAC manufactured by an upgraded process to HEXAVAC manufactured by the current process when given to healthy infants at 2, 4 & 6 months of age followed by a booster dose at 12 months of ageThe vaccine is indicated for primary and booster vaccination of children against six infectious diseases: diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis caused by 3 types of poliovirus (type 1,2 and 3), and invasive infections caused by Haemophilus influenza type b.EUCTR2005-002578-31-CZSanofi Pasteur MSD S.N.C.800
进行中（未招募）
1 期
A controlled, double-blind and randomized study, to compare the immunogenicity and safety of HEXAVAC manufactured by an upgraded process to HEXAVAC manufactured by the current process when given to healthy infants at 2, 4 & 6 months of age followed by a booster dose at 12 months of ageThe vaccine is indicated for primary and booster vaccination of children against six infectious diseases: diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis caused by 3 types of poliovirus (type 1,2 and 3), and invasive infections caused by Haemophilus influenza type b.EUCTR2005-002578-31-SKSanofi Pasteur MSD S.N.C.800
招募中
3 期
The effect of Sacubitril/Valsartan in preventing heart disease in high-risk patients undergoing chemotherapy with anthracyclinesAnthracyclinesCardiotoxicityC14.280Heart FailureRBR-5q4gm5bHospital Erasto Gaertner
已完成
2 期
Study of the tetanus vaccine vax-TET®-5TETANUSRPCEC00000156Finlay Institute, Center of Research and Production of Vaccines.472
已完成
不适用
A randomized, double-blind and controlled study of clearing heat and resolving depression in the treatment of bipolar depression and fire heat depressioBipolar disorderITMCTR2200005825Beijing Anding Hospital, Capital Medical University